文献速递妇科

利用子宫内膜癌替代支付模型(ECAP)估算低风险子宫内膜癌的节省潜力:妇科肿瘤学会子宫内膜癌替代支付模型报告的配套论文

Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model.
PubMed 文献 · Gynecol Oncol · 2018-03-01

该研究比较了美国商业保险(MarketScan,2009-13年)和公共保险(Medicare,2014年)中子宫内膜癌子宫切除术患者的支付模式,发现商业保险平均总支付为30,839美元,公共保险为19,183美元;优化模型中,微创手术率提高5%、住院时间降低10%、急诊就诊/再入院降低10%,可使商业保险和公共保险的平均病例支付分别降低903美元(2.9%)和1243美元(5.9%)。

要点

  • 商业保险子宫内膜癌手术平均总支付30,839美元,公共保险为19,183美元。
  • 开腹手术平均支付最高,公共保险25,553美元,商业保险35,357美元。
  • 商业保险患者中7.6%在术后60天内再入院,11.7%有急诊就诊。

核心结论

  • ECAP模型表明,美国公共保险与商业保险对子宫内膜癌手术治疗的支付存在差异,且存在节省成本的机会。
  • 微创手术率的小幅提高以及急诊就诊/再入院率和住院时间的降低,可为子宫内膜癌诊疗带来可观的节省。

研究设计与样本

  • 研究比较了商业保险(MarketScan数据,2009-13年)和公共保险(Medicare,2014年)中接受子宫切除术的子宫内膜癌患者的全国实践模式和支付。
  • 纳入的MarketScan患者为29,558例,Medicare患者为377例。
  • 支付范围包括从术前30天到术后60天的住院和门诊支付,并按手术方式(开腹、机器人、腹腔镜)分层。

主要发现

  • Medicare平均总支付为19,183美元(标准差10,844美元),MarketScan为30,839美元(标准差19,911美元)。
  • 开腹手术的平均支付最高:Medicare为25,553美元(标准差11,870美元),MarketScan为35,357美元(标准差21,670美元),其后为机器人和腹腔镜。
  • MarketScan患者中,7.6%在术后60天内再入院,11.7%有急诊就诊。
  • 再入院的每位患者中位支付为14,474美元(四分位距8,584至26,149美元),急诊就诊的中位支付为6,327美元(四分位距1,369至29,153美元)。
  • 在优化模型中,微创手术率提高5%、住院时间降低10%、急诊就诊/再入院降低10%,使MarketScan平均病例支付降低903美元(2.9%),Medicare降低1,243美元(5.9%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To design an endometrial cancer (EC) alternative payment (ECAP) model focused on surgical management of EC, as well as identify drivers of cost in order to develop opportunities for cost-savings while maintaining quality of care. METHODS: National practice patterns and reimbursements were compared between private payers (MarketScan data, years 2009-13) and public payers (Medicare, year 2014) of EC patients who underwent hysterectomy. An episode of care for EC included the hysterectomy, stratified by surgical approach (laparotomy versus robotic versus laparoscopy), and in- and outpatient reimbursements from 30days preoperatively to 60days postoperatively. Reimbursements were categorized into cost centers. A decision model informed modifiable components influencing overall reimbursements for EC surgical care. Variations in length of stay (LOS), emergency department (ED visits), and readmissions were analyzed to create an optimal care model. RESULTS: A total of MarketScan (n=29,558) and Medicare (n=377) patients were included. Mean total reimbursement for an episode of care was $19,183 (SD $10,844) for Medicare and $30,839 (SD $19,911) for MarketScan. Mean reimbursements were greatest for abdominal cases in Medicare ($25,553; SD $11,870) and MarketScan ($35,357; SD $21,670), followed by robotic and laparoscopic. Among MarketScan patients, 7.6% of women were readmitted within 60days after surgery and 11.7% had an evaluation in the ED. The median reimbursement per patient for readmission was $14,474 (IQR $8584 to $26,149), and for ED visit was $6327 (IQR $1369 to $29,153). In an optimized care model, increasing the rate of minimally invasive surgery by 5% while reducing LOS by 10% and ED visits/readmissions by 10%, lowered the average case reimbursement by $903 (2.9%) for MarketScan and $1243 (5.9%) for Medicare. CONCLUSION: An ECAP model demonstrates that reimbursements vary by public versus commercial payers in the U.S. for the surgical management of endometrial cancer patients, and that opportunities for cost savings exist. Nominal increases in the rate of minimally invasive surgery and reduction in the rate of ED visits/readmissions and length of stay can result in substantial savings for endometrial cancer care.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wright JD, Havrilesky LJ, Cohn DE, et al. Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model. Gynecol Oncol. 2018. PMID: 29496293. doi:10.1016/j.ygyno.2018.02.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。